Pharmaceutical compounds
AssigneeRafael Pharmaceuticals, Inc.
InventorsRobert Shorr, Robert Rodriguez, Paul Bingham, Lakmal Boteju, Thomas Kwok, James Marecek
Life of this patent
Estimating the term…
Abstract
Therapeutically-effective amounts of novel analogs or derivatives of alkyl fatty acids, such as but not limited to lipoic acid, and pharmaceutical formulations comprising such analogs or derivatives and pharmaceutically-acceptable carriers therefor, are useful for the treatment, prevention, imaging, and/or diagnosis of medical disorders.
Claims25
An alkyl fatty acid analog selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
An alkyl fatty acid analog selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof.
An alkyl fatty acid analog selected from the group consisting of:
- and a pharmaceutically acceptable salt thereof.
An alkyl fatty acid analog having the general formula:
- wherein:
- x is 1-16;
- R1 and R2 are independently alkylaryl or alkylheteroaryl, provided that R1 and R2 are not acyl;
- and
- R5 is one of the following:
- —NH2 substituted by a CnH2n+1 alkyl group substituted only by amino that is optionally substituted;
- —NH2 substituted by a CnH2n+1 alkyl group substituted by —SO3H, —SO2NH2 , —SO2NH(alkyl) or —SO2N(alkyl)2;
- saturated heterocyclic group;
- or
- hydrogen;
- wherein n is 1-16;
- or a salt thereof.
A method of treating a disease selected from primary melanoma, metastatic melanoma, lung cancer, liver cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, uterine cancer, cervical cancer, bladder cancer, kidney cancer, colon cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, and a sarcoma, comprising administering to a patient in need thereof a therapeutically effective amount of at least one alkyl fatty acid analog of Formula I, II, or III to treat the disease, wherein Formula I is represented by:
- wherein:
- x is 1-16;
- R1 and R2 are independently alkylaryl or alkylheteroaryl, provided that R1 and R2 are not acyl;
- and
- R5 is one of the following:
- —NH2 substituted by a CnH2n+1 alkyl group substituted by amino that is optionally substituted;
- —NH2 substituted by a CnH2n+1 alkyl group substituted by —SO3H, —SO2NH2 , —SO2NH(alkyl) or —SO2N(alkyl)2;
- saturated heterocyclic group;
- or
- hydrogen;
- wherein n is 1-16;
- or a salt thereof;
- Formula II is represented by:
- or a salt thereof;
- and
- Formula III is represented by:
- or a salt thereof.
Dependencies are inferred from the claim text.